Potent, Orally Active GPIIb/IIIa Antagonists Containing a Nipecotic Acid Subunit. Structure-Activity Studies Leading to the Discovery of RWJ-53308 was written by Hoekstra, William J.;Maryanoff, Bruce E.;Damiano, Bruce P.;Andrade-Gordon, Patricia;Cohen, Judith H.;Costanzo, Michael J.;Haertlein, Barbara J.;Hecker, Leonard R.;Hulshizer, Becky L.;Kauffman, Jack A.;Keane, Patricia;McComsey, David F.;Mitchell, John A.;Scott, Lorraine;Shah, Rekha D.;Yabut, Stephen C.. And the article was included in Journal of Medicinal Chemistry in 1999.Computed Properties of C15H28N2O2 This article mentions the following:
Although i.v. administered antiplatelet fibrinogen receptor (GPIIb/IIIa) antagonists have become established in the acute-care clin. setting for the prevention of thrombosis, orally administered drugs for chronic use are still under development. Herein, the authors present details from the authors exploration of structure-activity surrounding the prototype fibrinogen receptor antagonist RWJ-50042, which was derived from a unique approach involving the 纬-chain of fibrinogen (Hoekstra et al. J. Med. Chem. 1995, 38, 1582). The authors analog studies culminated in the discovery of RWJ-53308 (I), a potent, orally active GPIIb/IIIa antagonist. To progress from RWJ-50042 to a suitable candidate for clin. development, the authors conducted a series of optimization cycles that employed solid-phase parallel synthesis for the rapid, efficient preparation of nearly 250 analogs, which were assayed for fibrinogen receptor affinity and inhibition of platelet aggregation induced by four different activators. This strategy produced several promising analogs for advanced study, including the 3-(3,4-methylenedioxybenzene)-尾-amino acid analog (significant improved in vivo potency) and the 3-(3-pyridyl)-尾-amino acid I (significantly improved potency, oral absorption, and duration of action). In dogs, I displayed significant ex vivo antiplatelet activity on oral administration at 1.0 mg/kg, 16% systemic oral bioavailability, minimal metabolic transformation, and an excellent safety profile. Addnl., I was efficacious in three in vivo thrombosis models: canine arteriovenous (AV) shunt (0.01-0.1 mg/kg, iv), guinea pig photoactivation-induced injury (0.3-3 mg/kg, iv), and guinea pig ferric chloride-induced injury (0.3-1 mg/kg, iv). On the basis of its noteworthy preclin. data, I was selected for clin. evaluation. In the experiment, the researchers used many compounds, for example, tert-Butyl [4,4′-bipiperidine]-1-carboxylate (cas: 171049-35-7Computed Properties of C15H28N2O2).
tert-Butyl [4,4′-bipiperidine]-1-carboxylate (cas: 171049-35-7) belongs to piperidine derivatives. Piperidine and its derivatives have become increasingly popular in many synthetic schemes. Some chemotherapeutic agents have piperidine moiety within their structure, foremost among them, vinblastine and raloxifene.Computed Properties of C15H28N2O2
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem